Daily Roundup | Lilly's amylin add-on brings more weight loss and more dropouts & Rafael plans NDA after NPC miss

September 30 edition, released October 1. Date references in the audio are anchored to September 30.Lilly's EloraTZP (eloralintide plus tirzepatide) reached 23.3% weight loss vs 14.8% for tirzepatide in a secondary Phase 2b comparison, while more patients stopped over adverse events. Rafael Holdings' Trappsol Cyclo missed its Phase 3 TRANSPORT-NPC goal in Niemann-Pick disease type C, yet a fourth-quarter filing is still planned. The daily roundup covers Roche's fenebrutinib Priority Review in MS, Merck's tulisokibart in hidradenitis suppurativa, Pierre Fabre's Ebvallo (tabelecleucel) resubmission and NorthStar's actinium-225 financing. Plus Connect Biopharma's rademikibart in COPD flares, with its safety caveats.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.